PDUFA dates May 2018: FDA calendar and catalysts.
0 PDUFA dates fell in May 2018. The FDA calendar also recorded 8 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in May 2018
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
May 2018: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 15, 2018 | Jeuveau (prabotulinumtoxina-xvfs) | EOLS | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| May 15, 2018 | Retacrit (epoetin alfa-epbx) | PFE | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 17, 2018 | Aimovig (erenumab-aooe) | AMGN | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 17, 2018 | nda210605 | VTRS | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| May 18, 2018 | Lokelma (sodium zirconium cyclosilicate) | AZN | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 25, 2018 | Kanjinti (trastuzumab-anns) | AMGN | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| May 31, 2018 | OLUMIANT® (baricitinib) | LLY | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 31, 2018 | Consensi (amlodipine besylate; celecoxib) | PPBT | FDA approval | — | Approved | openFDA Drugs@FDA |
May 2018: dated readouts
No events in this view.
Questions
What PDUFA dates are in May 2018?
0 PDUFA dates fell in May 2018. The FDA calendar also recorded 8 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.